Eli Lilly and Company has emerged as in the development and tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant ability to improve glycemic control and reduce cardiovascular risks. The complex manufacturing process of tirzepatide involves a series of meticulous processes